Search

Your search keyword '"Endeman, Henrik"' showing total 599 results
Start Over Author "Endeman, Henrik"
599 results on '"Endeman, Henrik"'

7. Effect of lung ultrasound-guided fluid deresuscitation on duration of ventilation in intensive care unit patients (CONFIDENCE): protocol for a multicentre randomised controlled trial

Author

Blok, Siebe G., Mousa, Amne, Brouwer, Michelle G., de Grooth, Harm-Jan, Neto, Ary Serpa, Blans, Michiel J., den Boer, Sylvia, Dormans, Tom, Endeman, Henrik, Roeleveld, Timo, Scholten, Harm, van Slobbe-Bijlsma, Eline R., Scholten, Erik, Touw, Hugo, van der Ven, Fleur Stefanie L. I. M., Wils, Evert-Jan, van Westerloo, David J., Heunks, Leo M. A., Schultz, Marcus J., Paulus, Frederique, and Tuinman, Pieter R.

Published
2023
Full Text
View/download PDF

12. Safety and Outcome of High-Flow Nasal Oxygen Therapy Outside ICU Setting in Hypoxemic Patients With COVID-19*

Author

Janssen, Matthijs L., Türk, Yasemin, Baart, Sara J., Hanselaar, Wessel, Aga, Yaar, van der Steen-Dieperink, Mariëlle, van der Wal, Folkert J., Versluijs, Vera J., Hoek, Rogier A.S., Endeman, Henrik, Boer, Dirk P., Hoiting, Oscar, Hoelters, Jürgen, Achterberg, Sefanja, Stads, Susanne, Heller-Baan, Roxane, Dubois, Alain V.F., Elderman, Jan H., Wils, Evert-Jan, Gajadin, Shailin, Cox, Laura, Grewal, Sanjeev, van Oosten, Julien, Vlasveld, Imro N., and Jacobs, Wouter

Published
2024
Full Text
View/download PDF

13. Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial

Author

Ewoldt, Tim M. J., Abdulla, Alan, Rietdijk, Wim J. R., Muller, Anouk E., de Winter, Brenda C. M., Hunfeld, Nicole G. M., Purmer, Ilse M., van Vliet, Peter, Wils, Evert-Jan, Haringman, Jasper, Draisma, Annelies, Rijpstra, Tom A., Karakus, Attila, Gommers, Diederik, Endeman, Henrik, and Koch, Birgit C. P.

Published
2022
Full Text
View/download PDF

17. Altered fibrin network structure and fibrinolysis in intensive care unit patients with COVID‐19, not entirely explaining the increased risk of thrombosis

Author

de Vries, Judith J., Visser, Chantal, Geers, Lotte, Slotman, Johan A., van Kleef, Nadine D., Maas, Coen, Bax, Hannelore I., Miedema, Jelle R., van Gorp, Eric C.M., Goeijenbier, Marco, van den Akker, Johannes P.C., Endeman, Henrik, Rijken, Dingeman C., Kruip, Marieke J.H.A., and de Maat, Moniek P.M.

Published
2022
Full Text
View/download PDF

18. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19

Author

Raadsen, Matthijs P., Gharbharan, Arvind, Jordans, Carlijn C. E., Mykytyn, Anna Z., Lamers, Mart M., van den Doel, Petra B., Endeman, Henrik, van den Akker, Johannes P. C., GeurtsvanKessel, Corine H., Koopmans, Marion P. G., Rokx, Casper, Goeijenbier, Marco, van Gorp, Eric C. M., Rijnders, Bart J. A., and Haagmans, Bart L.

Published
2022
Full Text
View/download PDF

19. Development and validation of an early warning model for hospitalized COVID-19 patients: a multi-center retrospective cohort study

Author

Smit, Jim M., Krijthe, Jesse H., Tintu, Andrei N., Endeman, Henrik, Ludikhuize, Jeroen, van Genderen, Michel E., Hassan, Shermarke, El Moussaoui, Rachida, Westerweel, Peter E., Goekoop, Robbert J., Waverijn, Geeke, Verheijen, Tim, den Hollander, Jan G., de Boer, Mark G. J., Gommers, Diederik A. M. P. J., van der Vlies, Robin, Schellings, Mark, Carels, Regina A., van Nieuwkoop, Cees, Arbous, Sesmu M., van Bommel, Jasper, Knevel, Rachel, de Rijke, Yolanda B., and Reinders, Marcel J. T.

Published
2022
Full Text
View/download PDF

28. Performance of the FebriDx Rapid Point-of-Care Test for Differentiating Bacterial and Viral Respiratory Tract Infections in Patients with a Suspected Respiratory Tract Infection in the Emergency Department

Author

Tong-Minh, Kirby, Daenen, Katrijn, Endeman, Henrik, Ramakers, Christian, Gommers, Diederik, van Gorp, Eric, van der Does, Yuri, Tong-Minh, Kirby, Daenen, Katrijn, Endeman, Henrik, Ramakers, Christian, Gommers, Diederik, van Gorp, Eric, and van der Does, Yuri

Abstract

FebriDx is a rapid point-of-care test combining qualitative measurements of C-reactive protein (CRP) and Myxovirus Resistance Protein A (MxA) using a disposable test device to detect and differentiate acute bacterial from viral respiratory tract infections. The goal of this study was to investigate the diagnostic accuracy of FebriDx in patients with suspected respiratory tract infections in the emergency department (ED). This was an observational cohort study, performed in the ED of an academic hospital. Patients were included if they had a suspected infection. The primary outcome was the presence of a bacterial or viral infection, determined by clinical adjudication by an expert panel. The sensitivity, specificity, and positive and negative predictive value of FebriDx for the presence of bacterial versus non-bacterial infections, and viral versus non-viral infections were calculated. Between March 2019 and November 2020, 244 patients were included. A bacterial infection was present in 41%, viral infection was present in 24%, and 4% of the patients had both viral and bacterial pathogens. FebriDx demonstrated high sensitivity in the detection of bacterial infection (87%), high NPV (91%) to rule out bacterial infection, and high specificity (94%) for viral infection in patients with a suspected infection in the ED.

Published
2024

29. A Systematic Review of the Pulmonary Microbiome in Patients with Acute Exacerbation COPD Requiring ICU Admission

Author

van der Bie, Sjoerd, Haaksma, Mark E., Vermin, Ben, van Assema, Hidde, van Gorp, Eric C.M., Langerak, Thomas, Endeman, Henrik, Snijders, Dominic, van den Akker, Johannes P.C., van Houten, Marlies A., van Lelyveld, Steven F.L., Goeijenbier, Marco, van der Bie, Sjoerd, Haaksma, Mark E., Vermin, Ben, van Assema, Hidde, van Gorp, Eric C.M., Langerak, Thomas, Endeman, Henrik, Snijders, Dominic, van den Akker, Johannes P.C., van Houten, Marlies A., van Lelyveld, Steven F.L., and Goeijenbier, Marco

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a major health concern. Acute exacerbations (AECOPD) may require intensive care unit (ICU) admission and mechanical ventilation. Acute infections and chronic colonization of the respiratory system are known to precipitate AECOPD. Detailed knowledge of the respiratory microbiome could lead to effective treatment and prevention of exacerbations.Objective: The aim of this review is to summarize the available evidence on the respiratory microbiome of patients with a severe AECOPD requiring mechanical ventilation and intensive care admission. Methods: A systematic literature search was conducted to identify the published papers until January 2023. The collected data were then subjected to qualitative analysis. After the first analysis, a secondary focused review of the most recent publications studying the relationship between microbiome and mortality in AECOPD was performed. Results: Out of 120 screened articles six articles were included in this review. Potentially pathogenic microorganisms (PPMs) were identified in 30% to 72% of the patients with community-acquired bacteria, gram-negative enteric bacilli, Stenotrophomonas and Pseudomonas being the most frequently isolated. During hospitalization, 21% of patients experienced colonization by PPMs. Adequate antimicrobial therapy resulted in the eradication of 77% of the identified PPMs. However, 24% of the bacteria displayed multi-drug resistance leading to prolonged or failure of eradication. Conclusion: PPMs are prevalent in a significant proportion of patients experiencing an AECOPD. The most identified PPMs include community-acquired pathogens and gram-negative enteric bacilli. Notably, no differences in mortality or duration of ventilation were observed between patients with and without isolated PPMs. However, the included studies did not investigate the vir

Published
2024

30. Exploring the Impact of Model-Informed Precision Dosing on Procalcitonin Concentrations in Critically Ill Patients:A Secondary Analysis of the DOLPHIN Trial

Author

Dräger, Sarah, Ewoldt, Tim M.J., Abdulla, Alan, Rietdijk, Wim J.R., Verkaik, Nelianne, Ramakers, Christian, de Jong, Evelien, Osthoff, Michael, Koch, Birgit C.P., Endeman, Henrik, Dräger, Sarah, Ewoldt, Tim M.J., Abdulla, Alan, Rietdijk, Wim J.R., Verkaik, Nelianne, Ramakers, Christian, de Jong, Evelien, Osthoff, Michael, Koch, Birgit C.P., and Endeman, Henrik

Abstract

Model-informed precision dosing (MIPD) might be used to optimize antibiotic treatment. Procalcitonin (PCT) is a biomarker for severity of infection and response to antibiotic treatment. The aim of this study was to assess the impact of MIPD on the course of PCT and to investigate the association of PCT with pharmacodynamic target (PDT) attainment in critically ill patients. This is a secondary analysis of the DOLPHIN trial, a multicentre, open-label, randomised controlled trial. Patients with a PCT value available at day 1 (T1), day 3 (T3), or day 5 (T5) after randomisation were included. The primary outcome was the absolute difference in PCT concentration at T1, T3, and T5 between the MIPD and the standard dosing group. In total, 662 PCT concentrations from 351 critically ill patients were analysed. There was no statistically significant difference in PCT concentration between the trial arms at T1, T3, or T5. The median PCT concentration was highest in patients who exceeded 10× PDT at T1 [13.15 ng/mL (IQR 5.43–22.75)]. In 28-day non-survivors and in patients that exceeded PDT at T1, PCT decreased significantly between T1 and T3, but plateaued between T3 and T5. PCT concentrations were not significantly different between patients receiving antibiotic treatment with or without MIPD guidance. The potential of PCT to guide antibiotic dosing merits further investigation.

Published
2024

31. The Value of Ischemic Cardiac Biomarkers to Predict Spontaneous Breathing Trial or Extubation Failure: A Systematic Review.

Author

Groenland, Carline N. L., Blijleven, Maud A., Ramzi, Imane, Dubois, Eric A., Heunks, Leo, Endeman, Henrik, Wils, Evert-Jan, and Baggen, Vivan J. M.

Subjects
EXTUBATION, BIOMARKERS, RESPIRATION, ARTIFICIAL respiration, VENTILATOR weaning
Abstract

Background: It is unclear whether other cardiac biomarkers than NT-proBNP can be useful in the risk stratification of patients weaning from mechanical ventilation. The aim of this study is to summarize the role of ischemic cardiac biomarkers in predicting spontaneous breathing trial (SBT) or extubation failure. Methods: We systematically searched Embase, MEDLINE, Web of Science, and Cochrane Central for studies published before January 2024 that reported the association between ischemic cardiac biomarkers and SBT or extubation failure. Data were extracted using a standardized form and methodological assessment was performed using the QUIPS tool. Results: Seven observational studies investigating four ischemic cardiac biomarkers (Troponin-T, Troponin-I, CK-MB, Myoglobin) were included. One study reported a higher peak Troponin-I in patients with extubation failure compared to extubation success (50 ng/L [IQR, 20–215] versus 30 ng/L [IQR, 10–86], p = 0.01). A second study found that Troponin-I measured before the SBT was higher in patients with SBT failure in comparison to patients with SBT success (100 ± 80 ng/L versus 70 ± 130 ng/L, p = 0.03). A third study reported a higher CK-MB measured at the end of the SBT in patients with weaning failure (SBT or extubation failure) in comparison to weaning success (8.77 ± 20.5 ng/mL versus 1.52 ± 1.42 ng/mL, p = 0.047). Troponin-T and Myoglobin as well as Troponin-I and CK-MB measured at other time points were not found to be related to SBT or extubation failure. However, most studies were underpowered and with high risk of bias. Conclusions: The association with SBT or extubation failure is limited for Troponin-I and CK-MB and appears absent for Troponin-T and Myoglobin, but available studies are hampered by significant methodological drawbacks. To more definitively determine the role of ischemic cardiac biomarkers, future studies should prioritize larger sample sizes, including patients at risk of cardiac disease, using stringent SBTs and structured timing of laboratory measurements before and after SBT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. A Systematic Review of the Pulmonary Microbiome in Patients with Acute Exacerbation COPD Requiring ICU Admission

Author

van der Bie, Sjoerd, primary, Haaksma, Mark E., additional, Vermin, Ben, additional, van Assema, Hidde, additional, van Gorp, Eric C. M., additional, Langerak, Thomas, additional, Endeman, Henrik, additional, Snijders, Dominic, additional, van den Akker, Johannes P. C., additional, van Houten, Marlies A., additional, van Lelyveld, Steven F. L., additional, and Goeijenbier, Marco, additional

Published
2024
Full Text
View/download PDF

36. Predicting Beta-Lactam Target Non-Attainment in ICU Patients at Treatment Initiation: Development and External Validation of Three Novel (Machine Learning) Models

Author

Wieringa, André, primary, Ewoldt, Tim M. J., additional, Gangapersad, Ravish N., additional, Gijsen, Matthias, additional, Parolya, Nestor, additional, Kats, Chantal J. A. R., additional, Spriet, Isabel, additional, Endeman, Henrik, additional, Haringman, Jasper J., additional, van Hest, Reinier M., additional, Koch, Birgit C. P., additional, and Abdulla, Alan, additional

Published
2023
Full Text
View/download PDF

39. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Author

van Kampen, Jeroen J. A., van de Vijver, David A. M. C., Fraaij, Pieter L. A., Haagmans, Bart L., Lamers, Mart M., Okba, Nisreen, van den Akker, Johannes P. C., Endeman, Henrik, Gommers, Diederik A. M. P. J., Cornelissen, Jan J., Hoek, Rogier A. S., van der Eerden, Menno M., Hesselink, Dennis A., Metselaar, Herold J., Verbon, Annelies, de Steenwinkel, Jurriaan E. M., Aron, Georgina I., van Gorp, Eric C. M., van Boheemen, Sander, Voermans, Jolanda C., Boucher, Charles A. B., Molenkamp, Richard, Koopmans, Marion P. G., Geurtsvankessel, Corine, and van der Eijk, Annemiek A.

Published
2021
Full Text
View/download PDF

47. Exploring the Impact of Model-Informed Precision Dosing on Procalcitonin Concentrations in Critically Ill Patients: A Secondary Analysis of the DOLPHIN Trial.

Author

Dräger, Sarah, Ewoldt, Tim M. J., Abdulla, Alan, Rietdijk, Wim J. R., Verkaik, Nelianne, Ramakers, Christian, de Jong, Evelien, Osthoff, Michael, Koch, Birgit C. P., and Endeman, Henrik

Subjects
CRITICALLY ill, CALCITONIN, SECONDARY analysis, DOLPHINS, ANTIBIOTIC residues
Abstract

Model-informed precision dosing (MIPD) might be used to optimize antibiotic treatment. Procalcitonin (PCT) is a biomarker for severity of infection and response to antibiotic treatment. The aim of this study was to assess the impact of MIPD on the course of PCT and to investigate the association of PCT with pharmacodynamic target (PDT) attainment in critically ill patients. This is a secondary analysis of the DOLPHIN trial, a multicentre, open-label, randomised controlled trial. Patients with a PCT value available at day 1 (T1), day 3 (T3), or day 5 (T5) after randomisation were included. The primary outcome was the absolute difference in PCT concentration at T1, T3, and T5 between the MIPD and the standard dosing group. In total, 662 PCT concentrations from 351 critically ill patients were analysed. There was no statistically significant difference in PCT concentration between the trial arms at T1, T3, or T5. The median PCT concentration was highest in patients who exceeded 10× PDT at T1 [13.15 ng/mL (IQR 5.43–22.75)]. In 28-day non-survivors and in patients that exceeded PDT at T1, PCT decreased significantly between T1 and T3, but plateaued between T3 and T5. PCT concentrations were not significantly different between patients receiving antibiotic treatment with or without MIPD guidance. The potential of PCT to guide antibiotic dosing merits further investigation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. The Clearance of Midazolam and Metabolites during Continuous Renal Replacement Therapy in Critically Ill Patients with COVID-19.

Author

Smeets, Tim J.L., de Geus, Hilde R.H., Valkenburg, Abraham J., Baidjoe, Lauren, Gommers, Diederik A.M.P.J., Koch, Birgit C.P., Hunfeld, Nicole G.M., and Endeman, Henrik

Subjects
COVID-19, RENAL replacement therapy, BUTORPHANOL, MIDAZOLAM, CRITICALLY ill, COVID-19 pandemic
Abstract

Introduction: Midazolam-based continuous intravenous sedation in patients admitted to the intensive care unit (ICU) was a necessity during the COVID-19 pandemic. However, benzodiazepine-based sedation is associated with a high incidence of benzodiazepine-related delirium and additional days on mechanical ventilation. Due to the requirement of high midazolam doses in combination with the impaired renal clearance (CL) of the pharmacological active metabolite 1-OH-midazolam-glucuronide (10% compared to midazolam), ICU patients with COVID-19 and continuous renal replacement therapy (CRRT) were at risk of unintended prolonged sedation. Several CRRT-related factors may have influenced the delivered CL of midazolam and its metabolites. Therefore, the aim of the study was to identify and describe these CRRT-related factors. Methods: Pre-filter blood samples and ultrafiltrate samples were collected simultaneously. Midazolam, 1-OH-midazolam, and 1-OH-midazolam-glucuronide plasma samples were analyzed using an UPLC-MS/MS method. The prescribed CRRT dose was corrected for downtime and filter integrity using the urea ratio (urea concentration in effluent/urea concentration plasma). CL of midazolam and its metabolites were calculated with the delivered CRRT dose (corrected for downtime and saturation coefficient [SD]). Results: Three patients on continuous venovenous hemodialysis (CVVHD) and 2 patients on continuous venovenous hemodiafiltration (CVVHDF) were included. Midazolam, 1-OH-midazolam, and 1-OH-midazolam-glucuronide concentrations were 2,849 (0–6,700) μg/L, 153 (0–295) μg/L, and 27,297 (1,727–39,000) μg/L, respectively. The SD was 0.03 (0.02–0.03) for midazolam, 0.05 (0.05–0.06) for 1-OH-midazolam, and 0.33 (0.23–0.43) for 1-OH-midazolam-glucuronide. The delivered CRRT CL was 1.4 (0–1.7) mL/min for midazolam, 2.7 (0–3.5) mL/min for 1-OH-midazolam, and 15.7 (4.0–27.7) mL/min for 1-OH-midazolam-glucuronide. Conclusions: Midazolam and 1-OH-midazolam were not removed during CVVHD and CVVHDF. However, 1-OH-midazolam-glucuronide was removed reasonably, approximately up to 43%. CRRT modality, filter integrity, and downtime affect this removal. These data imply a personalized titration of midazolam in critically ill patients with renal failure and awareness for the additional sedative effects of its active metabolites. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Predicting individualized treatment effects of corticosteroids in community-acquired-pneumonia: a data-driven analysis of randomized controlled trials

Author

Smit, Jim M., primary, van der Zee, Philip A., additional, Stoof, S. C.M., additional, van Genderen, Michel E., additional, Snijders, Dominic, additional, Boersma, Wim G., additional, Confalonieri, Paola, additional, Salton, Francesco, additional, Confalonieri, Marco, additional, Shih, Mei-Chiung, additional, Meduri, Gianfranco U., additional, Dequin, Pierre-Francois, additional, Le Gouge, Amelie, additional, Lloyd, Melanie, additional, Karunajeewa, Harin, additional, Bartminski, Grzegorz, additional, Fernandez-Serrano, Silvia, additional, Suarez-Cuartin, Guillermo, additional, van Klaveren, David, additional, Briel, Matthias, additional, Schoenenberger, Christof M., additional, Steyerberg, Ewout W., additional, Gommers, Diederik A.M.P.J., additional, Bax, Hannelore I., additional, Bos, W J W., additional, van de Garde, Ewoudt, additional, Wittermans, Esther, additional, Grutters, Jan C., additional, Blum, Claudine A., additional, Christ-Crain, Mirjam, additional, Torres, Antoni, additional, Motos, Anna, additional, Reinders, Marcel J.T., additional, van Bommel, Jasper, additional, Krijthe, Jesse H., additional, and Endeman, Henrik, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results